Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials

作者
Guanghui Gao,Shengxiang Ren,Aiwu Li,Jianfang Xu,Qinghua Xu,Chunxia Su,Jian Guo,Qinfang Deng,Caicun Zhou
出处
期刊:International Journal of Cancer [Wiley]
卷期号:131 (5): E822-9 被引量:133
标识
DOI:10.1002/ijc.27396
摘要

Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for second-line or third-line indication in previously treated advanced Non-small-cell lung cancer (NSCLC) patients. The results of comparing the EGFR-TKI with standard platinum-based doublet chemotherapy as the first-line treatment in advanced NSCLC patients with activated EGFR mutation were still controversial. A meta-analysis was performed to derive a more precise estimation of these regimens. Finally, six eligible trials involved 1,021 patients were identified. The patients receiving EGFR-TKI as front-line therapy had a significantly longer progression-free survival (PFS) than patients treated with chemotherapy [median PFS was 9.5 versus 5.9 months; hazard ratio (HR)=0.37; 95% confidence intervals (CI)=0.27-0.52; p<0.001]. The overall response rate (ORR) of EGFR-TKI was 66.60%, whereas the ORR of chemotherapy regimen was 30.62%, which was also a statistically significant favor for EGFR-TKI [relative risk (RR)=5.68; 95% CI=3.17-10.18; p<0.001]. The overall survival (OS) was numerically longer in the patients received EGFR-TKI than patients treated by chemotherapy, although the difference did not reach a statistical significance (median OS was 30.5 vs. 23.6 months; HR=0.94; 95% CI=0.77-1.15; p=0.57). Comparing with first-line chemotherapy, treatment of EGFR-TKI achieved a statistical significantly longer PFS, higher ORR and numerically longer OS in the advanced NSCLC patients harboring activated EGFR mutations, thus, it should be the first choice in the previously untreated NSCLC patients with activated EGFR mutation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
江江的应助被zgw采纳,获得10
1秒前
科研小陈完成签到,获得积分10
1秒前
Clover04的应助被sjy采纳,获得10
1秒前
1秒前
张玉龙发布了新的文献求助10
1秒前
mkl发布了新的文献求助10
2秒前
Jane2024完成签到,获得积分10
2秒前
maaicui完成签到,获得积分10
2秒前
小浒发布了新的文献求助10
3秒前
Akim的应助被歪歪采纳,获得10
3秒前
Apple完成签到,获得积分10
3秒前
爆米花的应助被yinxinyi采纳,获得10
3秒前
Canma完成签到 ,获得积分10
3秒前
cwb完成签到,获得积分10
3秒前
4秒前
4秒前
oui发布了新的文献求助10
4秒前
DL完成签到 ,获得积分10
4秒前
干净的珍完成签到,获得积分20
5秒前
6秒前
6秒前
霸气小兔子完成签到,获得积分10
7秒前
Gumyu发布了新的文献求助50
7秒前
长安发布了新的文献求助10
7秒前
许木完成签到,获得积分10
7秒前
77发布了新的文献求助20
8秒前
其实我是橙色完成签到,获得积分10
8秒前
超级丸子发布了新的文献求助10
8秒前
8秒前
潇湘学术发布了新的文献求助10
8秒前
乐乐的应助被yuhanli采纳,获得10
9秒前
9秒前
整齐的尔蓉完成签到,获得积分10
9秒前
10秒前
在水一方的应助被aaa采纳,获得10
10秒前
VDoo完成签到,获得积分10
11秒前
yeguo完成签到,获得积分10
11秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253